Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613 (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Cranbury, NJ, May 26, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the positive results of
a single-arm, open-label, Phase 1 study of CPI-613 (devimistat) with gemcitabine and nab-paclitaxel in patients with locally advanced or metastatic pancreatic cancer, will be presented in a
poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. The results will be presented by Dr. Angela Tatiana Alistar, M.D., Medical
Director of Gastrointestinal (GI) Medical Oncology at Morristown Medical Center and principal investigator on the trial.
Rafafel_Pharma_PHP_Graphic_Updated_V3The presentation titled, “Abstract #4635: A single-arm, open-label, Phase 1 study of CPI-613 (devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally
advanced or metastatic pancreatic adenocarcinoma,” includes the results of a two-year Phase 1 study consisting of gemcitabine and nab-paclitaxel in 26 patients with locally advanced or
metastatic pancreatic cancer to determine maximum tolerated dose (MTD), safety, and preliminary efficacy of devimistat in combination with chemotherapy. Overall, the treatment was well-tolerated
and demonstrated positive results that show devimistat can be safely administered with gemcitabine and nab-paclitaxel at doses up to 1,500 m/g2.
“We’re proud to share our findings at ASCO 2020, to announce the latest positive Phase 1 results of our lead compound devimistat in the treatment of patients with pancreatic cancer,” said
Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “These findings give us a glimpse of the promising work underway, as we continue the momentum of inspiring hope for patients with
hard-to-treat cancers, including pancreatic cancer.”
“There is a significant need to enhance our current standard of care options in pancreatic cancer,” said Dr. Alistar. “When we started this trial, I anticipated good tolerance of devimistat in
combination with the gemcitabine/nab-paclitaxel regimen and am thrilled to see that the results met this expectation in full.”
Lesen Sie auch
Presentation Details:
Title: Abstract #4635: A single-arm, open-label, Phase 1 study of CPI-613 (devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic
pancreatic adenocarcinoma